(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Results and outcomes of use of multicatheter interstitial high-dose-rate (HDR) brachytherapy (BT) to deliver accelerated partial-breast irradiation (APBI) in a large cohort of women treated in a three-physician private practice setting over 10 years and 9 months are reported.

Richard B. Young, BA, Clinton A. Medbery III, MD, Marianne M. Young, MD, Astrid E. Morrison, MD; Frank C. Love Cancer Institute, St. Anthony Hospital

Purpose: To report results and outcomes of use of multicatheter interstitial high-dose-rate (HDR) brachytherapy (BT) to deliver accelerated partial-breast irradiation (APBI) in a large cohort of women treated in a three-physician private practice setting over 10 years and 9 months.

Materials and Methods: A total of 241 selected patients with Tis-2 N0-1mic breast cancer without an extensive intraductal component and with negative surgical margins were treated after breast-conserving surgery (BCS) with APBI using HDR BT. Three physicians performed the procedures as part of a comprehensive radiation oncology practice. Median patient age was 61 years. Dosage regimen was initially 34 Gy in 10 fractions over 4 elapsed days; subsequently, 32 Gy in 8 fractions over 3–4 elapsed days was used. Target volume was the surgical resection bed with a 1.5–2.0-cm margin. Ultrasound guidance was used in 231 cases, and mammographic stereotactic guidance was used in 10 cases. Overall median follow-up was 67.8 months and 67.4 months in surviving patients. Local breast and regional control, cancer-specific survival (CSS), disease-free survival (DFS), overall survival (OS), late effects, and cosmesis were evaluated.

Results: Four (1.54%) local recurrences were observed. Four (1.54%) “elsewhere” breast failures (different quadrant) were observed. All local and elsewhere failures recurred 18 to 42 months after treatment. Twenty patients died of intercurrent disease, five died of breast cancer, and one is alive with metastatic breast cancer. OS and CSS rates were 89.6% and 97.9%, respectively, with a median follow-up of 67.4 months. Cosmesis was excellent or good in 96.7% of cases. Fat necrosis requiring surgical intervention occurred in 28 patients (10.8%). Median V200 in patients who developed necrosis was 13.6 cc; median V200 in those without development of necrosis was 12.0 cc. Five (2.1%) patients developed telangiectasia > 1 cm2. Three (1.25%) patients developed breast abscess requiring surgical intervention.

Conclusions: APBI using HDR multicatheter interstitial implants is feasible in small private practice with dedicated brachytherapists, yielding excellent long-term results comparable with large academic institutional series and clinical trials and also comparing favorably with the more common external beam regimens.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content